[New Stock IPO]Zhaoyan New Drug 61,127, nearly 540,000 people subscribed for 309 times oversubscribed, 5% of the lottery rate (with distribution results)-Hong Kong Economic Times-News Channel-Market News-IPO

▲ [New shares IPO]Zhaoyan new drug 61,27, nearly 540,000 people subscribed for 309 times oversubscribed, the rate of 5% for the first hand signing (with distribution results)

Zhaoyan New Drug （06127）
According to the results of the IPO, Zhaoyan New Drug is priced at 151 yuan per share, and the net fund raised is 6.286 billion yuan. Zhaoyan New Drug has a 5% lottery rate, and 60 lots (6000 shares) can be won.【Assignment result】

• Zhaoyan New Drug Allotment Results and Prospectus Details
▼Click on the picture to enlarge

–

–

+5
–

+4
–

–

–

–

–
–

Zhaoyan’s new medicines in Hong Kong’s public sale section recorded a total of nearly 540,000 subscriptions, which was oversubscribed by 309 times, and the international sale was oversubscribed by about 25 times.

Zhaoyan New Drug is the CRO (Contract Research Organization) of China’s new drug pharmacology and toxicology research. Most of its revenue comes from the provision of non-clinical research services, (1) drug safety evaluation; (2) pharmacokinetic research; (3) pharmacology And pharmacodynamic research.

Zhaoyan New Drug will be listed on February 26.

To track IPO news, you can browse 【New IPO】 Or use【IPO】Gadgets

[IPO]Who is Feng Yuxia, the major shareholder of Zhaoyan New Medicine 6127?Five must-knows to subscribe for Zhaoyan’s new drugs

[New shares IPO]Zhaoyan New Medicine 6127 IPO admission fee is 15,252 yuan, A share premium is nearly 30%

【Enhance the cash flow of SMEs. Up to $1,500 reward! Terms and conditions apply]

[MPF Perspective]Can tax deductible voluntary contribution points enjoy 12% total return?

Editor in charge: Liang Haoshuo

–